Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

ASCO 2018：阿帕替尼联合化疗能显著改善驱动基因阴性NSCLC的结局

2018-06-01 MedSci MedSci原创

ASCO阿帕替尼NSCLC
关注

研究摘要：阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC研究背景目前，系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗，然而二线治疗的疗效有待进一步提高。阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂，具有显著的抗血管生成活性。该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性。研究方法一个双臂、开放、多中心临

研究摘要：阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC


研究背景

目前，系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗，然而二线治疗的疗效有待进一步提高。阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂，具有显著的抗血管生成活性。该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性。

研究方法

一个双臂、开放、多中心临床试验，入组一线化疗失败、不能切除的驱动基因阴性局部晚期或晚期NSCLC患者。受试者按照2：1随机分入试验组与对照组，试验组患者口服阿帕替尼（500mg）联合多西他赛（75mg/m2）或培美曲塞（500mg/m2）4周期，然后阿帕替尼（500mg）单药维持治疗直到疾病进展、毒性不耐受或患者要求停药。对照组患者则仅接受多西他赛（75mg/m2）或培美曲塞（500mg/m2）4周期的治疗并随访。该研究的主要终点为无进展生存期（PFS），次要终点为总生存期（OS）、疾病控制率（DCR）和安全性。

研究结果

试验组与对照组的中位生存期（mPFS）分别为6.3个月 vs 2.6个月，DCR为86.67% vs 37.5%，OS仍在随访中。常见不良反应包括高血压、手足皮肤反应、疲劳、皮疹、腹泻、蛋白尿和骨髓抑制。

结论
阿帕替尼联合化疗能显著改善不能切除的驱动基因阴性局部晚期或晚期NSCLC患者的PFS和DCR，不良反应耐受性良好。这一联合治疗方案有望成为晚期NSCLC的二线标准治疗，但仍需深入的研究以进一步确认其疗效与安全性。（临床试验登记号：NCT0325672121）

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938854, encodeId=a3671938854d9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jan 04 06:10:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661483, encodeId=a61116614834c, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Sat Apr 13 10:10:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411724, encodeId=af221411e246c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jun 03 09:10:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320619, encodeId=fc0532061966, content=目前.系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗.然而二线治疗的疗效有待进一步提高.阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂.具有显著的抗血管生成活性.该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性., beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Jun 01 19:48:38 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320599, encodeId=2d34320599c2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 01 18:28:33 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2019-01-04 quxin068

    #ASC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1938854, encodeId=a3671938854d9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jan 04 06:10:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661483, encodeId=a61116614834c, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Sat Apr 13 10:10:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411724, encodeId=af221411e246c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jun 03 09:10:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320619, encodeId=fc0532061966, content=目前.系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗.然而二线治疗的疗效有待进一步提高.阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂.具有显著的抗血管生成活性.该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性., beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Jun 01 19:48:38 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320599, encodeId=2d34320599c2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 01 18:28:33 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2019-04-13 751943081_32627957

    #驱动基因#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1938854, encodeId=a3671938854d9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jan 04 06:10:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661483, encodeId=a61116614834c, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Sat Apr 13 10:10:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411724, encodeId=af221411e246c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jun 03 09:10:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320619, encodeId=fc0532061966, content=目前.系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗.然而二线治疗的疗效有待进一步提高.阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂.具有显著的抗血管生成活性.该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性., beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Jun 01 19:48:38 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320599, encodeId=2d34320599c2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 01 18:28:33 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-03 oliver170

    #联合化疗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938854, encodeId=a3671938854d9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jan 04 06:10:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661483, encodeId=a61116614834c, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Sat Apr 13 10:10:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411724, encodeId=af221411e246c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jun 03 09:10:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320619, encodeId=fc0532061966, content=目前.系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗.然而二线治疗的疗效有待进一步提高.阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂.具有显著的抗血管生成活性.该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性., beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Jun 01 19:48:38 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320599, encodeId=2d34320599c2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 01 18:28:33 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-01 有备才能无患

    目前.系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗.然而二线治疗的疗效有待进一步提高.阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂.具有显著的抗血管生成活性.该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1938854, encodeId=a3671938854d9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jan 04 06:10:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661483, encodeId=a61116614834c, content=<a href='/topic/show?id=34a110150800' target=_blank style='color:#2F92EE;'>#驱动基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101508, encryptionId=34a110150800, topicName=驱动基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b94625296381, createdName=751943081_32627957, createdTime=Sat Apr 13 10:10:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411724, encodeId=af221411e246c, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Jun 03 09:10:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320619, encodeId=fc0532061966, content=目前.系统性化疗依然是驱动基因阴性晚期NSCLC的标准治疗.然而二线治疗的疗效有待进一步提高.阿帕替尼是一种新型的VEGFR-2酪氨酸激酶抑制剂.具有显著的抗血管生成活性.该前瞻性研究旨在探索阿帕替尼联合化疗二线治疗不能切除的驱动基因阴性局部晚期或晚期NSCLC的有效性和安全性., beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Jun 01 19:48:38 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320599, encodeId=2d34320599c2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Jun 01 18:28:33 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-01 1e0f8808m18(暂无匿称)

    学习了.谢谢分享!

    0

相关资讯

ASCO-GU 2018：寡转移性前列腺癌的临床处理

2018年ASCO GU研讨会于当地时间2月8日在旧金山拉开帷幕，吸引了超过4300名来自世界各地的泌尿生殖肿瘤专家和基础研究学者参与。论坛首日的内容是关于前列腺癌的临床和基础研究进展，寡转移性前列腺癌（Oligometastatic Prostate Cancer）的诊疗是本次论坛的讨论热点之一。

ASCO 2018：乳腺癌抗HER2辅助治疗，6个月就足够了？

摘要编号：506时间：6月4日8:00 AM~11:00 AM专场：局部乳腺癌/区域乳腺癌/新辅助治疗形式：口头报告  对于HER2阳性乳腺癌而言，曲妥珠单抗1年辅助治疗是目前各大指南推荐的标准方案。曾有多项研究试图在不影响疗效的前提下缩短抗HER2治疗时间，但均未能取得成功。 PERSEPHONE研究是一项由英国研究者开展的大型多中心、非劣效、随机对照Ⅲ期临床试验，

代表中国发声 华西医院四项研究登陆ASCO GU

华西医院携四项晚期前列腺癌和肾癌相关研究亮相2018年美国临床肿瘤学会泌尿肿瘤研讨会。

ASCO 2018：T细胞恶性肿瘤，奈拉滨出手相救

摘要编号：10500时间：6月2日3:00 PM~6:00 PM专场：儿科肿瘤形式：口头报告  奈拉滨（Nelarabine，NEL）是一种T细胞特异性药物，FDA批准用于至少两种化疗方案失败的患者。COG AAL0434评价了在新诊断的T-ALL和T-LL患者中，将其加入ABFM化疗方案时的安全性和有效性。 AAL0434登记了1895例患者（2007-2014年）

ASCO 2018：肺癌筛查，任重而道远！

摘要编号：6504时间：6月1日2:45 PM~5:45 PM专场：健康服务研究，临床信息学以及护理质量 形式：口头报告  肺癌不仅是中国癌症相关第一死因，也是名副其实的美国“癌王”。作为癌症筛查的重点，美国预防服务工作组（USPSTF）从2013年开始，推荐年龄55～80岁，吸烟30包/年以上（仍在吸烟或戒烟时间＜15年）的美国人，每年进行一次低剂量CT（LDCT）

关注！ASCO大会上的中国创新药全新临床数据

在本届ASCO大会，又有众多中国创新药的临床数据亮相。

Baidu
map
Baidu
map
Baidu
map